Despite initial enthusiasm, 1, 2, 3 the use of pharmacogenetics has remained limited to
investigation in only a few clinical fields such as oncology and psychiatry. 4, 5, 6, 7, 8 The …

Abstract Background: Proton pump inhibitors (PPIs) are mainly metabolized by cytochrome
P450 2C19 (CYP2C19) and used as the first‐line therapy for gastroesophageal reflux …

Background & Aims We aimed to compare the efficacy of genotypic resistance–guided
therapy vs empirical therapy for eradication of refractory Helicobacter pylori infection in …

Peptic ulcer bleeding is a common disease and recurrent bleeding is an independent risk
factor of mortality. Infusion with proton pump inhibitors (PPIs) prevents recurrent bleeding …

BACKGROUND & AIMS: Previous observational studies reported that concomitant use of
clopidogrel and proton pump inhibitors (PPIs) in patients with prior acute coronary syndrome …

Background/Purpose Clarithromycin-based standard triple therapy is still commonly adopted
by 81.4% of physicians in real-world practice but yields low eradication rates. Therefore, we …

Background Whether extending the treatment length and the use of high-dose
esomeprazole may optimize the efficacy of Helicobacter pylori eradication remains …

Background There is conflicting evidence regarding the potential interaction between
clopidogrel and proton pump inhibitors (PPIs), with observational studies suggesting an …

Background Imaging-enhanced endoscopy enhances the contrast of the mucosal surface
and helps in the diagnosis of gastroesophageal reflux disease. However, whether the …

Background and aims Gastroesophageal reflux disease (GERD) is emerging as a clinical
complication in the Orient. The consensus comprises recommendations to GERD control …